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Infections caused byMycobacterium abscessus andMycobacterium massiliense are on the rise among humans. Although macro-
lides, including clarithromycin (CLR) and azithromycin (AZM), are key antibiotics for the treatment ofM. abscessus andM.
massiliense infections, treatment regimens for these infections are still largely undefined. In this study, we evaluated the in vitro,
ex vivo, and in vivo activities of moxifloxacin (MXF) in combination with macrolides against clinically isolatedM. abscessus and
M. massiliense strains. Overall, CLR, AZM, and MXF alone showed activity against both species in vitro, ex vivo, and in vivo.
WhenMXF was combined with a macrolide againstM. abscessus isolates, antagonism was observed in 65.4% (17/26) of the
strains with CLR and 46.2% (12/26) of the strains with AZM in vitro as well as in 66.7% (10/15) of the strains with CLR and
40.0% (6/15) of the strains with AZM inmacrophages as determined by the fractional inhibitory concentration index. In con-
trast, either indifferent or synergistic effects of the MXF-macrolide combinations were observed against onlyM. massiliense
strains. Moreover, a murine infectionmodel showed similar results. Antagonism between theMXF andmacrolide combinations
was observed in five out of sevenM. abscessus strains, while indifferent and synergistic effects for these combinations were ob-
served for three of the sixM. massiliense strains tested, respectively. In conclusion, the activity of MXF in combination with a
macrolide differed forM. abscessus andM. massiliense infections and the addition of MXF to macrolide therapy had no benefit
for the treatment ofM. abscessus infections.
Mycobacterium abscessus is the most common etiologic agentof lung diseases that are caused by the rapidly growing my-
cobacteria (RGM) (12, 13, 18), and it has emerged as an important
pathogen in patientswith cystic fibrosis (25, 33, 36).M.abscessus is
resistant to most antibiotics currently available and thus is very
difficult to treat (23, 24, 34). Isolates are usually susceptible only to
some parenteral agents (amikacin, cefoxitin, and imipenem) and
to oral macrolides (clarithromycin [CLR] and azithromycin
[AZM]) (12, 13, 18). Combination therapy of intravenous amika-
cin with cefoxitin or imipenem and an oral macrolide for 2 to 4
months has been recommended by theAmericanThoracic Society
(ATS)/Infectious Diseases Society of America (IDSA) and many
other experts (12, 13, 18). After initial therapy, macrolide admin-
istration plus at least one other antibiotic agent to which the or-
ganism is susceptible should be used for treatment. However, this
option is limited because of high in vitro resistance rates to the
various other oral agents used against M. abscessus isolates (12,
13, 18).
Oral fluoroquinolones have also been used in the treatment of
RGM infection. Although fluoroquinolones cannot be used as a
single-drug therapy due to the risk of developing resistance mu-
tations (45), some experts have suggested that “holding” regimens
of a macrolide plus a fluoroquinolone may be helpful during pe-
riods between pulsed intravenous antibiotic therapies (14). Fluo-
roquinolones have been used in many patients during combina-
tion treatment ofM. abscessus lung disease in clinical practices (23,
24), but the combined activities of a fluoroquinolone with a mac-
rolide againstM. abscessus have not been evaluated systemically in
experimental studies or clinical trials.
Recently,M. abscessus was divided into three separate subspe-
cies: Mycobacterium abscessus sensu stricto, Mycobacterium
massiliense, and Mycobacterium bolletii (1, 3). M. massiliense is
now recognized as a separate species fromM. abscessus, and treat-
ment response rates to CLR-based antibiotic therapy are much
higher in patients with M. massiliense than in those with M. ab-
scessus lung disease (28, 31). To gain greater insight into the opti-
mal therapeutic strategy forM. abscessus andM.massiliense infec-
tions, we evaluated the in vitro, ex vivo, and in vivo activities of
moxifloxacin (MXF) in combination with macrolides against
clinical isolates ofM. abscessus andM. massiliense.
MATERIALS AND METHODS
Clinical isolate sources, growth conditions, and inoculumpreparation.
A total of 62 clinical isolates consisting of 31 M. abscessus and 31 M.
massiliense isolates were recovered from patients who were diagnosed at
the Samsung Medical Center (Seoul, South Korea). All patients met the
diagnostic criteria for nontuberculous mycobacterium (NTM) lung dis-
ease published by theAmericanThoracic Society (18). The data are part of
an ongoing prospective observational cohort study investigating NTM
lung disease (ClinicalTrials.gov identifier NCT00970801). The study pro-
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tocol was approved by the institutional review board of the Samsung
Medical Center (IRB approval 2008-09-016), and written informed con-
sent was obtained from all participants. Two reference strains,M. absces-
susATCC 19977T (ATCC,Manassas, VA) andM.massilienseCIP108297T
(Institut Pasteur, Paris, France), were always included as controls for each
set of experiments.
Precise species identification of M. abscessus and M. massiliense was
performed using sequence analysis targeting the rpoB and hsp65 genes as
well as an analysis of the variable-number tandem repeat (VNTR) profile
as previously described (2, 8). All strains were initially cultured in 7H9
broth (Becton, Dickinson, Franklin Lakes, NJ) supplemented with oleic
acid-albumin-dextrose-catalase (OADC; Becton, Dickinson, Sparks,
MD) for 10 days at 37°C. Single-cell suspensions of each strain were pre-
pared as previously described with slight modifications (41). Seed lots of
each strain were kept in small aliquots at80°C until use. Tenfold serial
dilutions from seed lots of each strain were plated on Middlebrook 7H10
agar (Becton, Dickinson) to quantify the number of organisms per milli-
liter.
Antimicrobials.MXFwas kindly provided by Bayer Schering Pharma
AG (Berlin, Germany). Two macrolides, CLR and AZM, were purchased
from Tokyo Chemical Industry Co. (TCI, Tokyo, Japan) and LKT Labo-
ratories, Inc. (St. Paul, MN), respectively. A common diluent (0.03% ace-
tic acid solution) for all of the antibiotics was included as a control in all of
the experiments. All of the stock drug solutions were freshly prepared for
each experiment and filter sterilized using a 0.22-m polycarbonate sy-
ringe filter (Millipore Corp., Bedford, MA).
In vitro susceptibility testing. MICs of all tested drugs were deter-
mined by broth microdilution assays according to the protocol set by the
Clinical and Laboratory Standards Institute (CLSI) (11). Briefly, the drugs
at final concentrations ranging from 0.125 to 128 g/ml in 7H9-OADC
broth were added to 96-well plates in 2-fold serial dilutions. The final
inoculum size was adjusted to 104 CFU/ml. Controls included the inocu-
lum without drug added (no-drug control) and the 1:100-diluted inocu-
lum (99% control). The MIC of each drug was defined as the lowest drug
concentration that inhibited more than 99% of the bacterial growth ob-
served in the drug-free medium after incubation at 37°C for 72 h. The
MIC50 and MIC90 levels were interpreted as the lowest concentration of
antibiotics that inhibited 50% and 90% of the isolates, respectively. All
assays were independently performed three times in triplicate.
Mice and preparation of bone marrow-derived macrophages
(BMDMs). Specific-pathogen-free female C57BL/6mice at 5 to 6weeks of
age were purchased from Japan SLC, Inc. (Shijuoka, Japan), and main-
tained under barrier conditions in a biosafety level 2 (BL-2) biohazard
animal facility at the Medical Research Center of Chungnam National
University. The animals were fed a sterile commercial mouse diet and
provided with water ad libitum. The animal experiments complied with
the ethical and experiment regulations for animal care at Chungnam Na-
tional University (approval no. 2008-04).
Murine bonemarrow-derivedmacrophages (BMDMs) were differen-
tiated for 6 days in macrophage colony-stimulating factor (M-CSF)-con-
taining media, as described previously (27). Briefly, bone marrow cells
from the femur and tibia were cultured in Dulbecco’s modified Eagle’s
medium (DMEM; HyClone, Logan, UT) containing 2 mM L-glutamine,
100 U/ml penicillin, 100 g/ml streptomycin, 10% fetal bovine serum,
and 20 ng/ml of recombinant M-CSF (R&D Systems, Minneapolis, MN)
at 37°C in the presence of 5% CO2. After 6 days, nonadherent cells were
removed, and the differentiated macrophages were incubated in anti-
biotic-free DMEM until use.
Antibiotic activities against intracellular bacteria within macro-
phages. The activities of drug combinations between macrolides and
MXF were evaluated for a reference strain and 14 clinical isolates of each
species, M. abscessus and M. massiliense, using a murine bone marrow-
derived macrophage system. These clinical isolates of each species were
selected based on the similarity of their MICs to that of MXF (ranging
from 0.5 to 2 g/ml).
Differentiated BMDMs were adjusted to a density of 5.0 105/well in
a 24-well tissue culture plate (Corning Life Sciences, Acton,MA) andwere
infected with each strain ofM. abscessus andM. massiliense for 4 h at the
ratio of 1 bacterium to 1 macrophage. This infectious dose of mycobacte-
ria did not affect the macrophage viability during the experiments, and
thus, the drug activity could be measured only against intracellular bac-
teria. The infected BMDMs were washed twice with DMEM to remove
extracellular bacteria and were cultivated for 24 h at 37°C in 5% CO2 to
allow the intracellular mycobacteria to adapt. To compare the antibiotic
activities of each individual drug and the MXF-macrolide combinations
against the intracellular bacteria, the mycobacterium-infected macro-
phages were treated with 10 g/ml of each drug or MXF-macrolide com-
binations at the same concentrations followed by incubation for an addi-
tional 48 h. At the indicated times (before and after treatment), the
macrophages were lysed with distilled water, and the number of CFU
within the cell lysates was determined using the plate countingmethod for
cultures grown on 7H10-OADC.
Evaluation of treatment efficacy in mice. Six clinical isolates of M.
abscessus and 5 clinical isolates of M. massiliense as well as the two refer-
ence strains were used for the therapeutic evaluation of each drug and the
MXF-macrolide combinations in mycobacterium-infected mice. Before
conducting the experiments, the minimum lethal dose (MLD) of each
strainwas determined using sixmice per strain, and 4-fold dilutions of the
MLD (4.0 106 to 1.0 107 CFU) were subsequently used in the in vivo
experiments. Six-week-old female C57BL/6J mice (36 mice per strain, 6
mice per drug) were infected with the selected dose of each strain by
intravenous injection via the tail vein. At 4 days postinfection, treatment
was initiatedwith the antimicrobial agents (100mg/kg of bodyweight/day
of each drug alone or in combination with 100 mg/kg/day of MXF). The
dose of each antibioticwas selected based on the results of previous studies
that determined the effective dose of each drug in murine infection mod-
els of other mycobacteria (5, 6, 32). Antimicrobial agents were adminis-
tered daily by oral gavage for 12 days. Controlmice for each strain received
the same volume of 0.03% acetic acid in distilled water over the same
period. At 16 days postinfection, six mice per group were euthanized, and
their livers, spleens, and lungs were aseptically collected for bacterial
counts. The numbers of viable bacteria in the organs were determined by
plating serial dilutions of the organ homogenates onto 7H10-OADC agar
plates. Colonies were counted after 5 days of incubation at 37°C. The
differences detectedwhen comparing the drug-treated groups and control
groups as well as among the drug-treated groups (drug alone versus com-
binations) are represented as the means of the log10 CFU the standard
deviation (SD) for each group of mice. This experiment was performed
twice.
Evaluation of combined drug action. Evaluation of the antimycobac-
terial activities of each drug alone and of the MXF-macrolide combina-
tions, the fractional inhibitory concentration (FIC) based on the MICs in
vitro, and the FICs based on CFU counts in macrophages and mice are
described below.
(i) Evaluation of combination activity in vitro. The effects of the
antibiotic combinations were determined by the fractional inhibitory
concentration (FIC) based on the MICs of each drug alone and of each
drug combination as previously described with slight modifications (19,
20, 26, 39). The concentration range of each antibiotic in combination
ranged from 1/16 the MIC to 4 times the MIC. The FIC index was calcu-
lated as follows: (MIC of drug A in combination)/(MIC of drug A alone).
The following definitions were used: synergism, FIC index of0.5; indif-
ference, FIC index of0.5 and2; and antagonism, FIC index of2. All
tests were performed in triplicate, and the results were averaged. For the
evaluations of the combined effects of MXF and macrolides, drug A was
defined as CLR or AZM. Synergy has been defined as a 2-fold reduction in
the MIC of the combination of antibiotics compared with each antibiotic
alone. Antagonism has been defined as a 2-fold increase in the MIC when
a combination of antibiotics is used. The in vitro interactions of the indi-
vidual macrolides in combination with MXF are summarized in Table 2.
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(ii) Determination of combination activity in macrophages and in
mice. To determine the effect of antibiotic interactions in macrophages
and in mice, the antibiotic activity of the combination treatment was
defined as the log10 CFU reduction as previously reported with slight
modifications (32, 40). Briefly, the antimycobacterial activity was assessed
by counting the CFU from the macrophage lysates or the homogenates of
inoculated organs on 7H10 agar supplemented with 10% OADC and de-
termining the log10 CFU per ml after 5 days.
In these calculations, x refers to the log10 CFU from the control
obtainedwith the drug combination and y refers to the lowestlog10 CFU
from the control obtained with each drug used alone. The interaction
between the drugs was assessed quantitatively by adopting the x/y quo-
tient method described by Hoffner et al. (20). An x/y value of 1 indicated
that there was no interaction between the two drugs and was interpreted
as indifference, an x/y value of0.5 indicated synergy, and an x/y value of
2.0 indicated antagonism.
Statistical analysis. The results in the text and tables are reported as
the mean standard deviation or as the number (percentage) of strains.
Comparisons between single drugs and drug combinations in the same
strain were analyzed usingWilcoxon’s matched pairs test. The differences
between the treatment groups in the same species were determined using
the Mann-Whitney nonparametric test. A comparison of treatment effi-
cacies for M. abscessus and M. massiliense with each drug combination
was performed with a chi-squared test. The differences were consid-
ered significant at a P value of 0.05. All statistical analyses were
performed using GraphPad Prism software (version 4.03; GraphPad
Software, San Diego, CA).
RESULTS
In vitro susceptibilities to macrolides andMXF. The antimicro-
bial activities of themacrolides were tested against 31M. abscessus
and 31 M. massiliense isolates in addition to the two reference
strains. TheMIC data for CLR, AZM, andMXF againstM. absces-
sus and M. massiliense are shown in Table 1. Overall, the MIC
range of CLR was lower than that of AZM for both M. abscessus
andM. massiliense. According to the CLSI,2 g/ml is regarded
as susceptible and 8 g/ml is regarded as resistant to CLR and
1 g/ml is regarded as susceptible and4 g/ml is regarded as
resistant to MXF (11). However, the breakpoint for AZM against
M. abscessus and M. massiliense has not been established. In this
study, M. abscessus and M. massiliense isolates were considered
susceptible if the MIC of AZM was16 g/ml and were consid-
ered resistant at32g/ml. These values were derived from both
the distribution of MICs and the MIC90 of CLR.
Among theM. abscessus isolates, six strains showed initial drug
resistance to both macrolides due to a point mutation in the ade-
nine at position 2058 (A2058) in the 23S rRNA gene (data not
shown). In contrast, none of theM. massiliense strains were resis-
tant to either macrolide. Interestingly, 4 of the 31 M. massiliense
isolates and the reference strain displayed MXF resistance, while
the MICs of MXF for all of theM. abscessus strains did not exceed
2 g/ml. The strains that showed initial resistance to any drug
were ruled out for subsequent experiments to prevent interference
in the determination of the combination activities of each drug.
Thus, M. abscessus and M. massiliense clinical isolates with no
considerable variation in MIC values upon each antimicrobial
agent were used to investigate the effects of the combined drugs.
MXF exhibited the lowest range of MIC values against the clinical
isolates tested in the study (0.25 to 2g/ml forM. abscessus and
0.25 to 8 g/ml for M. massiliense), while AZM had a wider
range of MIC values than did MXF or CLR.
In vitro activities of macrolide-MXF combinations. The ac-
tivities of the drug combinations CLR-MXF and AZM-MXF were
compared with those of single drugs for each of the strains that
were found to be susceptible to each of the three drugs (Table 2).
When antagonism was defined as an FIC index of 2.0, 17
(65.4%) and 12 (46.2%) of 26M. abscessus isolates showed antag-
onism for the CLR-MXF and AZM-MXF combinations, respec-
tively.Notably, synergism resulting from the combination ofMXF
with either CLR or AZM was observed for one strain only.
However, when the macrolide and MXF combinations were
tested against the 28 M. massiliense strains, both CLR-MXF and
AZM-MXF combinations generally resulted in an indifferent in-
teraction for the same 16 isolates (57.1%). The synergistic effects
of CLR-MXF and AZM-MXF were observed for 11 isolates
(39.3%) and 10 isolates (35.7%), respectively. However, antago-
TABLE 1 In vitro antimicrobial activities of macrolides and moxifloxacin against 62 clinical isolates ofM. abscessus andM. massiliense and each
reference strain
Species (no. of
isolates) Agent
No. of strains distributed at each MIC (g/ml)
Resistance rate, no. of
strains (%)0.25 0.5 1 2 4 8 16 32 64
M. abscessus (32) AZM 4 5 15 2 3 3 6a (18.8)
CLR 3 15 5 2 1 1 1 1 3 6a (18.8)
MXF 6 7 10 9
M. massiliense (32) AZM 1 2 6 23
CLR 20 12
MXF 12 10 3 3 3b 1 4b (12.5)
a Six isolates ofM. abscessus that were resistant to both macrolides due to a point mutation in the 23S rRNA were excluded from the subsequent experiments.
b Four isolates ofM. massiliense that were resistant to moxifloxacin were excluded from the subsequent experiments.
TABLE 2 In vitro antimicrobial activities of the combinations of a
macrolide and moxifloxacin againstM. abscessus andM. massiliense
Species and agents
No. (%) of isolates with combination activitya
Synergism Indifference Antagonism
M. abscessus
(n 26)
CLR-MXF 1 (3.8) 8 (30.8) 17 (65.4)
AZM-MXF 1 (3.8) 13 (50.0) 12 (46.2)
M. massiliense
(n 28)
CLR-MXF 11 (39.3) 16 (57.1) 1 (3.6)
AZM-MXF 10 (35.7) 16 (57.1) 2 (7.1)
a The effects of antibiotic combinations were determined by the fractional inhibitory
concentration (FIC): synergism, FIC index of0.5; indifference, FIC index of0.5 and
2.0; antagonism, FIC index of2.0.
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nism was observed for one isolate (3.6%) when combining MXF
with CLR and for two isolates (7.1%) when MXF was combined
with AZM. A statistical analysis using a chi-squared test showed a
significant difference in the responses of the M. abscessus and M.
massiliense species to the MXF-macrolide combinations (P 
0.005).
Activities of macrolide-MXF combinations against intracel-
lular bacteria.Next, we investigated the effect of the drug combi-
nations on intracellular bacteria in comparison with the effects of
the single drugs using the x/y quotient method (Table 3). Among
the 15M. abscessus strains susceptible to macrolides andMXF, 10
(66.7%) of the strains showed antagonism for theCLR-MXF com-
bination, and 6 (40.0%) of the strains showed antagonism for the
AZM-MXF combination when the antagonistic effect was defined
as an x/y value of 2.0. Synergism for both drug combinations
was also observed in one strain, which was the same strain that
showed synergism in vitro. In contrast, a large proportion of the
M.massiliense strains revealed indifference forCLR-MXF (60.0%)
and AZM-MXF (66.7%). A synergistic effect was observed in five
M. massiliense (33.3%) strains when treated with CLR-MXF and
three strains (20%) when treated with AZM-MXF. A statistical
analysis using a chi-squared test showed a significant difference
between theM. abscessus andM. massiliense groups for the effects
of the MXF-macrolide combinations (P 0.005).
In vivo activities of macrolide-MXF combinations. The ther-
apeutic efficacies of single drugs and drug combinations were
evaluated in a murine model of M. abscessus and M. massiliense
infection. Treatment with each drug alone, CLR-MXF, and AZM-
MXFwas initiated 3 days postinfection and administered daily for
12 days. All experiments were performed twice, and similar results
were obtained for both experiments. Although the activity of each
drug differed depending on the tested strains, most mice that re-
ceived macrolides or MXF alone revealed a significant decrease in
the bacterial load in all of the organs examined (P 0.001) com-
pared to the control mice. The therapeutic effects of each drug
alone and the drug combination treatments against each M. ab-
scessus and M. massiliense-infected mice are shown in Tables S1
and S2 in the supplemental material. Similar to the results ob-
tained from the in vitro and ex vivo investigations, the combina-
tion of amacrolide andMXFwas not superior to either drug alone
in the treatment of M. abscessus infection. Among the 7 strains
tested, 5 and 2 strains showed antagonism and an indifferent effect
for both macrolide-MXF combinations, respectively (Fig. 1). In
contrast, in vivo synergism between CLR-MXF and AZM-MXF
was observed against 3 of theM.massiliense strains (Fig. 2). Indif-
ferent effects in theM.massiliense-infectedmicewere observed for
3 strains for both of the macrolide-MXF combinations (Fig. 2). A
statistical analysis using a chi-squared test showed a significant
difference between theM. abscessus andM. massiliense groups for
treatment with the MXF-macrolide combinations (P 0.005).
DISCUSSION
Treatment of the most common NTM pathogens improved with
the introduction ofmacrolide-containing regimens, but the treat-
ment outcome for M. abscessus lung disease remains disappoint-
ing (22–24, 34), because of the relatively few therapeutic alterna-
tives for the treatment compared to other mycobacteria. Thus,
novel therapeutic approaches are needed because clinical failures
are frequently encountered.
Fluoroquinolones such as MXF showed good in vitro activity
against M. abscessus clinical isolates in some studies (21, 38). In
fact, MXF is an attractive treatment option because it can be ad-
ministered orally for a long duration. However, there is only lim-
ited evidence regarding the clinical efficacy of MXF against M.
abscessus andM. massiliense.
Our results clearly demonstrated two findings: (i) MXF hin-
ders the activity of macrolides and (ii) the antagonism between
MXF and the macrolide was relatively common against the M.
FIG 1 Activities of clarithromycin, azithromycin, andmoxifloxacin alone and
macrolide-moxifloxacin combinations against 7M. abscessus isolates in mice.
(A) Significant differences are shown in the in the log10 CFU/lung between
treatments with clarithromycin alone andwith the clarithromycin-moxifloxa-
cin combination. (B) Significant differences in the log10 CFU/lung between
treatments with azithromycin alone and with the azithromycin-moxifloxacin
combination. The P value versus control mice was evaluated usingWilcoxon’s
matched pairs test. *, P 0.05; **, P 0.005; and ***, P 0.001.
TABLE 3 Evaluation of the antimicrobial activities of drug
combinations against intracellular bacteria in bone marrow-derived
macrophages
Species and agents
No. (%) of isolates with combination activitya
Synergism Indifference Antagonism
M. abscessus
(n 15)
CLR-MXF 1 (6.6) 4 (26.7) 10 (66.7)
AZM-MXF 1 (6.6) 8 (53.3) 6 (40.0)
M. massiliense
(n 15)
CLR-MXF 5 (33.3) 9 (60.0) 1 (6.7)
AZM-MXF 3 (20.0) 10 (66.7) 2 (13.3)
a The effects of antibiotic combinations were determined by adopting the x/y quotient
method. Synergism, an x/y value of0.5; indifference, a value of0.5 and2.0;
antagonism, a value of2.0.
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abscessus isolates compared to the M. massiliense isolates. Thus,
our study demonstrated that combining macrolides with MXF
provided no advantage for the treatment ofM. abscessus lung dis-
ease.
MXFhas been reported to have clinical efficacy forM. abscessus
infection. A recent prospective observational study demonstrated
that CLR-MXF combination therapy for postacupuncture cuta-
neous M. abscessus infections resulted in a more rapid resolution
of the cutaneous lesions than did the use of a CLR-amikacin com-
bination (9). Moreover, MXF has been shown to be effective
against experimentally induced M. abscessus keratitis and in hu-
man cases of that disorder (7, 10, 37). However, MXF obviously
interferes with CLR activity in over 65% of the tested strains ofM.
abscessus in our models, indicating that many factors should be
considered in explaining such a different result. For example, the
pharmacokinetic and pharmacodynamic properties of MXF may
differ according to the type of disease (cutaneous infection versus
pulmonary infection), and differences in the drug dose and ther-
apeutic regimens could also influence the results.
In contrast to the efficacy of medication regimens for nonpul-
monary diseases such as skin infection, no antibiotic regimen
based on in vitro susceptibilities has been shown to produce effec-
tive treatment for patients with M. abscessus lung disease (18). A
lack of correlation between the in vitro results and the in vivo
effects regarding drug activity was also observed in this study. For
example,MXF showed activity in vitro superior to that of CLR and
AZM against both M. abscessus and M. massiliense. However,
monotherapy with MXF was less effective than that with AZM in
the murine infection model. Thus, our results indicate that it may
be difficult to predict the in vivo therapeutic effects of MXF based
on its in vitroMIC test result. These results are in agreement with
those of a similar study conducted on the Mycobacterium avium
complex (32). Factors that could account for this may be differ-
ences in the ability of the strain to grow in the medium versus in
vivo or differences in the penetrating power of the antibiotics.
Similarly, many studies have demonstrated that MXF andmacro-
lides are more effective during bacterial replication than when the
bacterial numbers approach the maximal values in stationary
phase (15, 16, 42).
Another factor that could affect the response to antibiotics is
the anatomic location of infection or between strains isolated
from hosts in different geographical regions. Notably, the in vitro
susceptibilities for MXF against M. abscessus varied with the iso-
lation source as well as between countries and patients infected
with the same strain. A previous study conducted using 21 strains
ofM. abscessus in Japan found that the MIC of MXF ranged from
2 to 32 g/ml with an MIC90 of 32 g/ml (35). Similarly, a study
conducted in Taiwan with 98 M. abscessus clinical isolates re-
ported an MIC range of 0.064 to 32 g/ml, also with an MIC90 of
32g/ml (22). However, a study performed in South Korea using
74 M. abscessus isolates showed that the MIC90 of MXF was 2
g/ml and that only five strains exceeded an MIC of 4 g/ml of
MXF (38). Interestingly, theMICs of MXF ofM. abscessus isolates
from 12 patients varied significantly more than the MICs of other
antibiotics, such as CLR and amikacin, in an outbreak of postacu-
puncture cutaneous infections caused byM. abscessus species be-
longing to the same genotype (9). Thus, there are significant geo-
graphic differences and patient variations in the MICs of MXF
against M. abscessus, and comparisons of the activity of MXF are
complicated by differences in the drug regimens and/or strains
used in the studies. Additional studies on different M. abscessus
andM. massiliense strains are needed to substantiate these obser-
vations.
In our study, the MICs of different antibiotics are reported
according to the species. To date, differential identification ofM.
abscessus and M. massiliense has not been intensively studied be-
cause they cause the same spectrum of diseases and because it is
difficult to discriminate between the two species using traditional
molecular methods (e.g., PCR-restriction fragment length poly-
morphism or sequence analysis of rpoB and hsp65) due to a lack of
polymorphisms in the region being tested (8, 17, 29). However,
recent studies suggest that the antibiotic susceptibilities and treat-
ment outcomes differ significantly between the two species (31).
In this study,M.massiliense showedmarked susceptibility to CLR,
while six isolates of M. abscessus were resistant to macrolides, re-
sults which are similar to previously reported findings (30). In
contrast, MXF showed a wider range of MICs against M. massil-
iense than didM. abscessus according to CLSI criteria for RGM. In
the same context, treatment efficacy forM.massiliense with MXF
alone was less than that for M. abscessus in our murine infection
model (Fig. 1 and 2). Thus, it is important to discriminate between
these two species prior to treatment because an empirical addition
of antibiotics to treatM. abscessus andM. massiliensemay be po-
tentially counterproductive.
The exact reasons for the antagonistic effect of MXF on the
actions of themacrolide are not known, but one possible explana-
FIG 2 Activities of clarithromycin, azithromycin, andmoxifloxacin alone and
macrolide-moxifloxacin combinations against 6 M. massiliense isolates in
mice. (A) Significant differences in the log10 CFU/lung between treatments
with clarithromycin alone and with the clarithromycin-moxifloxacin combi-
nation. (B) Significant differences in the log10 CFU/lung between treatments
with azithromycin alone and with the azithromycin-moxifloxacin combina-
tion. The P value versus controlmice was evaluated usingWilcoxon’smatched
pairs test.
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tion has been suggested in previous studies. Tomioka et al. showed
that CLR decreases the activities of gatifloxacin and levofloxacin
against M. avium complex strains in vitro (44). Kohno et al. also
reported that the activity of CLR againstM. avium complex strains
was attenuated when combined with fluoroquinolones, including
MXF, using both in vitro and in vivo models (32). Another study
by Bermudez et al. revealed that the MXF-AZM combination was
significantly less active than AZM alone for the treatment of mice
infected withM. avium (4). In addition, protein synthesis inhibi-
tors, such as CLR, interfere with the lethal antibacterial activities
of fluoroquinolones (43).
A limitation of this study is that we did not investigate whether
the combinations at various concentrations of each drug provided
better antimycobacterial activity. An additional shortcoming of
the present study is that we employed a systemic infection model
via intravenous injection rather than an aerosol infection model.
Conclusively, the present study provides evidence that MXF
negatively influences the treatment outcome in experimental
models ofM. abscessus infectionwhen combinedwithmacrolides.
Our study demonstrates, for the first time, that MXF has signifi-
cantly different effects onM. abscessus andM. massiliense.
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